Products

Adriamycin Injection (Doxorubicin by Pfizer): The Critical Anthracycline for Multi-Modal Oncology – Global Supply by Ernest Oncology In the intensive field of 2026 oncology, Adriamycin Injection—the gold-standard Doxorubicin formulation from Pfizer—remains one of the most powerful and versatile cytotoxic agents available. Known colloquially in clinical settings as the “Red Devil“ due to its distinct color and potent efficacy, Adriamycin is a cornerstone of curative-intent chemotherapy for a vast range of solid tumors and hematologic malignancies. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Pfizer’s Adriamycin Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical cold-chain logistics. What is Adriamycin Injection? Adriamycin is a sterile pyrogen-free solution for intravenous injection, typically available in strengths of 10 mg, 50 mg, and 200 mg Vials. It belongs to the anthracycline antibiotic family and works by interfering with the DNA and RNA of rapidly dividing cancer cells. Primary Therapeutic Indications Breast Cancer: A foundational component of adjuvant and neoadjuvant regimens (e.g., the AC regimen). Hematologic Malignancies: Essential for treating Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia (AML), Hodgkin’s Disease, and Non-Hodgkin’s Lymphomas. Soft Tissue & Osteogenic Sarcomas: One of the most effective agents for aggressive connective tissue cancers. Ovarian & Bladder Carcinoma: Used in advanced or metastatic settings where multi-agent chemotherapy is required. Pediatric Oncology: Widely utilized in protocols for Wilms' tumor and neuroblastoma. Technical Product Profile: Adriamycin Feature Technical Specification Brand Name Adriamycin Manufacturer Pfizer Active Ingredient Doxorubicin Hydrochloride Pharmacological Class Anthracycline Topoisomerase II Inhibitor Available Strengths “10 mg, 50 mg, 200 mg Vials“ Dosage Form Injectable Solution / Lyophilized Powder Storage 2°C to 8°C (36°F to 46°F); Refrigerated transport required Mechanism of Action: The Multi-Pathway Attack Adriamycin exerts its cytotoxic effects through several complex mechanisms: Intercalation: The molecule slides between DNA base pairs, physically blocking the replication and transcription machinery. Topoisomerase II Inhibition: It stabilizes the complex between DNA and the enzyme Topoisomerase II, preventing the re-sealing of DNA strands and causing lethal double-strand breaks. Free Radical Generation: It triggers the production of reactive oxygen species (ROS) that damage cell membranes and proteins, further inducing apoptosis (cell death). Clinical Administration & Safety Vesicant Warning: Adriamycin is a potent vesicant. Extreme care must be taken during IV administration to prevent extravasation, which can cause severe tissue necrosis. Cardiac Monitoring: The drug is associated with cumulative dose-related cardiotoxicity. Baseline and periodic LVEF (Left Ventricular Ejection Fraction) monitoring via MUGA or ECHO scans is mandatory. Hematologic Monitoring: Patients typically experience significant nadir in white blood cell and platelet counts; regular CBC monitoring is essential. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology ensures that global healthcare providers have uninterrupted access to Pfizer’s oncology portfolio. We maintain a robust cold-chain infrastructure to ensure the biological integrity of every vial from India to your destination. United Kingdom & London: Direct supply to NHS Trusts and private clinics in London, ensuring MHRA-compliant handling and delivery. United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Pfizer exports via Indian distribution channels. Abu Dhabi & UAE: Fast-track shipping to the Middle East's premier cancer centers and health authorities. Australia & South Africa: Strategic distribution to regional wholesalers to support national healthcare tenders and oncology protocols. Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality Pfizer oncology products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Pemetrex Injection (Pemetrexed): Advanced Multi-Targeted Antifolate for Thoracic Oncology – Global Supply by Ernest Oncology In the precision-driven landscape of 2026 oncology, Pemetrex Injection (containing the active ingredient Pemetrexed) remains a foundational treatment for non-small cell lung cancer (NSCLC) and mesothelioma. As a multi-targeted antifolate, Pemetrex is designed to disrupt the metabolic pathways of malignant cells with high specificity. Its integration into first-line and maintenance protocols has redefined survival benchmarks for patients globally. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Pemetrex Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Pemetrex Injection? Pemetrex is a sterile, lyophilized powder for intravenous infusion, typically available in strengths of 100 mg and 500 mg Vials. It is a chemically unique folate antimetabolite that targets multiple enzymes essential for cell replication. Primary Therapeutic Indications Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Used in combination with cisplatin for first-line treatment, and as a single agent for maintenance or second-line therapy. Malignant Pleural Mesothelioma: The gold-standard treatment, used in combination with cisplatin, for patients whose disease is unresectable or who are not candidates for surgery. Combination Therapy: Increasingly used in 2026 in triplet combinations with immunotherapy to maximize pathological complete response (pCR) rates. Technical Product Profile: Pemetrex (Pemetrexed) Feature Technical Specification Brand Name Pemetrex Active Ingredient Pemetrexed Disodium Pharmacological Class Antifolate Antimetabolite Available Strengths “100 mg, 500 mg Vials“ Manufacturer Leading GMP Indian Partners Dosage Form Lyophilized Powder for Reconstitution (IV Infusion) Storage 20°C to 25°C; Reconstituted solution is stable for up to 24 hours Mechanism of Action: Triple Enzyme Inhibition Pemetrex exerts its cytotoxic effect by disrupting the folate-dependent metabolic processes necessary for cell replication: Multi-Targeted Blockade: Unlike older antifolates, Pemetrex inhibits three key enzymes: Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT). DNA/RNA Deprivation: By shutting down these pathways, the drug prevents the synthesis of thymidine and purine nucleotides, effectively starving the cancer cell of the “building blocks“ needed for DNA synthesis. Selectivity: It shows a high affinity for non-squamous tumor cells, making it a highly specialized tool for specific NSCLC histologies. Clinical Administration & Safety Pre-medication Protocol: To reduce toxicity, patients must receive Folic Acid and Vitamin B12 supplementation starting prior to the first dose. Dexamethasone is also administered to prevent skin rashes. Renal Monitoring: Pemetrexed is primarily eliminated by the kidneys; therefore, calculating Creatinine Clearance (CrCl) is mandatory before every cycle. Hematologic Monitoring: Patients should be monitored for myelosuppression (primarily neutropenia and thrombocytopenia). Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Pemetrex. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Bulk procurement options for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier medical cities and government healthcare authorities. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock for national lung cancer programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Pemnat Injection (Pemetrexed): Precision Antifolate Therapy for Lung Cancer – Global Supply by Ernest Oncology In the evolving landscape of 2026 thoracic oncology, Pemnat Injection (containing the active ingredient Pemetrexed) remains a foundational treatment for non-small cell lung cancer (NSCLC) and mesothelioma. As a multi-targeted antifolate, Pemnat is globally recognized for its ability to significantly improve survival outcomes when used in first-line, maintenance, and second-line settings. Its refined efficacy profile makes it a non-negotiable component of modern oncology protocols. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Pemnat Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Pemnat Injection? (Mechanism & Clinical Indications) Pemnat is a sterile, lyophilized powder for intravenous infusion, typically available in strengths of 100 mg and 500 mg Vials. It is a chemically unique folate antimetabolite that targets multiple enzymes essential for cell replication. Primary Therapeutic Indications Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Used in combination with cisplatin for first-line treatment, and as a single agent for maintenance or second-line therapy. Malignant Pleural Mesothelioma: The gold-standard treatment, used in combination with cisplatin, for patients whose disease is unresectable or who are not candidates for curative surgery. Combination Therapy: Often utilized alongside immunotherapy agents (such as pembrolizumab) to enhance clinical response in advanced metastatic settings. Technical Product Profile: Pemnat (Pemetrexed) Feature Technical Specification Brand Name Pemnat Active Ingredient Pemetrexed Disodium Pharmacological Class Antifolate Antimetabolite Available Strengths “100 mg, 500 mg Vials“ Manufacturer “Leading GMP Indian Partners (e.g., Natco Pharma)“ Dosage Form Lyophilized Powder for Reconstitution (IV Infusion) Storage 20°C to 25°C; Reconstituted solution is stable for up to 24 hours Mechanism of Action: Triple Enzyme Inhibition Pemnat exerts its cytotoxic effect by disrupting the folate-dependent metabolic processes necessary for cell replication: Multi-Targeted Blockade: Unlike older antifolates, Pemnat inhibits three key enzymes: Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT). DNA/RNA Deprivation: By shutting down these pathways, the drug prevents the synthesis of thymidine and purine nucleotides, effectively starving the cancer cell of the “building blocks“ needed for DNA and RNA synthesis. Selectivity: It shows a high affinity for non-squamous tumor cells, making it a highly specialized tool for specific NSCLC histologies. Clinical Administration & Safety Pre-medication Protocol: To reduce toxicity, patients must receive Folic Acid and Vitamin B12 supplementation starting prior to the first dose. Dexamethasone is also administered to prevent skin rashes. Renal Monitoring: Pemetrexed is primarily eliminated by the kidneys; therefore, calculating Creatinine Clearance (CrCl) is mandatory before every cycle. Hematologic Monitoring: Patients should be monitored for myelosuppression (primarily neutropenia and thrombocytopenia). Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Pemnat. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Bulk procurement options for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier medical cities and government healthcare authorities. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock for national lung cancer programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Alimta Injection (Pemetrexed): Precision Antifolate Therapy for Lung Cancer – Global Supply by Ernest Oncology In the evolving landscape of 2026 thoracic oncology, Alimta Injection (containing the active ingredient Pemetrexed) remains a foundational treatment for non-small cell lung cancer (NSCLC) and mesothelioma. As a multi-targeted antifolate, Alimta is globally recognized for its ability to significantly improve survival outcomes when used in first-line, maintenance, and second-line settings. Its refined efficacy profile makes it a non-negotiable component of modern oncology protocols. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Alimta Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Alimta Injection? (Mechanism & Clinical Indications) Alimta is a sterile, lyophilized powder for intravenous infusion, typically available in strengths of 100 mg and 500 mg Vials. It is a chemically unique folate antimetabolite that targets multiple enzymes essential for cell replication. Primary Therapeutic Indications Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Used in combination with cisplatin for first-line treatment, and as a single agent for maintenance or second-line therapy. Malignant Pleural Mesothelioma: The gold-standard treatment, used in combination with cisplatin, for patients whose disease is unresectable or who are not candidates for curative surgery. Combination Therapy: Often utilized alongside immunotherapy agents (such as pembrolizumab) to enhance clinical response in advanced metastatic settings. Technical Product Profile: Alimta (Pemetrexed) Feature Technical Specification Brand Name Alimta Active Ingredient Pemetrexed Disodium Pharmacological Class Antifolate Antimetabolite Available Strengths “100 mg, 500 mg Vials“ Manufacturer Eli Lilly / Leading WHO-GMP Indian Partners Dosage Form Lyophilized Powder for Reconstitution (IV Infusion) Storage 20°C to 25°C; Reconstituted solution is stable for up to 24 hours Mechanism of Action: Triple Enzyme Inhibition Alimta exerts its cytotoxic effect by disrupting the folate-dependent metabolic processes necessary for cell replication: Multi-Targeted Blockade: Unlike older antifolates, Alimta inhibits three key enzymes: Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT). DNA/RNA Deprivation: By shutting down these pathways, the drug prevents the synthesis of thymidine and purine nucleotides, effectively starving the cancer cell of the “building blocks“ needed for DNA and RNA synthesis. Selectivity: It shows a high affinity for non-squamous tumor cells, making it a highly specialized tool for specific NSCLC histologies. Clinical Administration & Safety Pre-medication Protocol: To reduce toxicity, patients must receive Folic Acid and Vitamin B12 supplementation starting prior to the first dose. Dexamethasone is also administered to prevent skin rashes. Renal Monitoring: Pemetrexed is primarily eliminated by the kidneys; therefore, calculating Creatinine Clearance (CrCl) is mandatory before every cycle. Hematologic Monitoring: Patients should be monitored for myelosuppression (primarily neutropenia and thrombocytopenia). Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Alimta. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Bulk procurement options for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier medical cities and government healthcare authorities. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock for national lung cancer programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Celzar Injection (Gemcitabine): Advanced Nucleoside Analog for Solid Tumors – Global Supply by Ernest Oncology In the intensive field of 2026 oncology, Celzar Injection (containing the active ingredient Gemcitabine) remains a cornerstone therapeutic for several challenging malignancies. As a nucleoside metabolic inhibitor, Celzar is globally recognized for its efficacy in disrupting cancer cell replication, particularly in pancreatic, lung, and breast cancers. Its predictable safety profile and versatility in combination therapies make it a staple in both curative and palliative chemotherapy regimens. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Celzar Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Celzar Injection? Celzar is a sterile solution or lyophilized powder for intravenous infusion, typically available in strengths of 200 mg and 1 g Vials. It is a pyrimidine antimetabolite that mimics the natural building blocks of DNA to halt tumor growth. Primary Therapeutic Indications Pancreatic Cancer: The gold-standard first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with Cisplatin for the first-line treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Breast Cancer: Used in combination with Paclitaxel for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-based chemotherapy. Ovarian Cancer: Utilized in combination with Carboplatin for patients with advanced ovarian cancer that has relapsed at least six months after completion of platinum-based therapy. Bladder Cancer: Frequently used in the gemcitabine-cisplatin (GC) regimen for advanced or metastatic transitional cell carcinoma. Technical Product Profile: Celzar (Gemcitabine) Feature Technical Specification Brand Name Celzar Active Ingredient Gemcitabine Hydrochloride Pharmacological Class Nucleoside Metabolic Inhibitor (Antimetabolite) Available Strengths “200 mg, 1 g Vials“ Manufacturer Leading GMP Indian Partners Dosage Form Injection / Lyophilized Powder for IV Infusion Storage 20°C to 25°C; Protect from light Mechanism of Action: DNA Synthesis Inhibition Celzar exerts its cytotoxic effect by “tricking“ the cancer cell during the DNA synthesis (S-phase) of the cell cycle: Metabolic Activation: Gemcitabine is metabolized intracellularly into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Masked Chain Termination: The active triphosphate is incorporated into the DNA strand. After one additional nucleotide is added, the DNA polymerase is unable to proceed, effectively “locking“ the DNA and preventing repair. Dual Action: It also inhibits the enzyme ribonucleotide reductase, reducing the pool of natural deoxynucleotides available for DNA synthesis. Clinical Administration & Safety Infusion Duration: Typically administered as an IV infusion over 30 minutes. Hematologic Monitoring: The primary dose-limiting toxicity is myelosuppression. Regular CBC (Complete Blood Count) monitoring is mandatory. Tolerability: Celzar is generally well-tolerated, often used in elderly populations or patients with lower performance status where more aggressive taxanes might be contraindicated. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Celzar. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Cytarine Injection (Cytarabine): The Essential Antimetabolite for Hematologic Malignancies – Global Supply by Ernest Oncology In the intensive field of 2026 hematology, Cytarine Injection (containing the active ingredient Cytarabine, also known as Ara-C) remains a cornerstone therapeutic agent. As a cell-cycle phase-specific antimetabolite, Cytarine is globally recognized for its efficacy in treating acute leukemias and other aggressive blood cancers. Its ability to inhibit DNA synthesis makes it an indispensable component of modern induction and consolidation protocols. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Cytarine Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical cold-chain logistics. What is Cytarine Injection? (Mechanism & Clinical Indications) Cytarine is a sterile solution or lyophilized powder for intravenous, subcutaneous, or intrathecal administration, typically available in strengths of 100 mg, 500 mg, and 1 g Vials. It is a pyrimidine nucleoside analog that effectively disrupts cancer cell replication during the S-phase of the cell cycle. Primary Therapeutic Indications Acute Myeloid Leukemia (AML): A critical agent for induction therapy, often used in the “7+3“ regimen, and for high-dose consolidation. Acute Lymphocytic Leukemia (ALL): A vital component in both pediatric and adult ALL treatment protocols. Chronic Myeloid Leukemia (CML): Utilized during the blast crisis phase to manage rapid leukemic cell proliferation. Meningeal Leukemia: Administered intrathecally for the prophylaxis and treatment of leukemia that has spread to the central nervous system (CNS). Non-Hodgkin’s Lymphoma: Used in aggressive or refractory lymphoma salvage regimens. Technical Product Profile: Cytarine (Cytarabine) Feature Technical Specification Brand Name Cytarine Active Ingredient Cytarabine (Ara-C) Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “100 mg, 500 mg, 1000 mg (1 g) Vials“ Manufacturer Leading GMP Indian Partners Dosage Form Solution / Lyophilized Powder for Injection Storage 15°C to 30°C; Protect from light Mechanism of Action: DNA Chain Termination Cytarine exerts its cytotoxic effect by “tricking“ rapidly dividing cells during DNA synthesis: Metabolic Activation: Cytarabine is intracellularly converted into its active form, Cytarabine Triphosphate (Ara-CTP). DNA Polymerase Inhibition: Ara-CTP competes with natural building blocks to inhibit DNA polymerase, the enzyme responsible for DNA assembly. Irreversible Damage: It incorporates itself into the DNA strand, acting as a “faulty link“ that halts elongation and triggers programmed cell death (apoptosis). S-Phase Specificity: Because it only affects cells actively synthesizing DNA, it is highly targeted toward aggressive leukemic blasts. Clinical Administration & Safety Route Versatility: Depending on the protocol, Cytarine can be given via rapid IV bolus, continuous IV infusion, or deep subcutaneous injection. Hematologic Monitoring: The primary dose-limiting toxicity is myelosuppression. Frequent Complete Blood Count (CBC) monitoring is mandatory. Neurotoxicity Risk: High-dose Cytarine (HiDAC) therapy requires careful screening for cerebellar toxicity and ocular side effects. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology bridges the gap between high-quality Indian pharmaceutical manufacturing and global patient needs. We ensure that every batch of Cytarine reaches its destination with full documentation and regulatory compliance. United Kingdom & London: Seamless supply to NHS Trusts and private hematology clinics via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and NCI-designated cancer centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier medical cities and government healthcare tenders. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring stable stock for national leukemia programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Cytosar Injection (Cytarabine): The Gold Standard Antimetabolite for Hematologic Malignancies – Global Supply by Ernest Oncology In the intensive landscape of 2026 hematology and oncology, Cytosar Injection (containing the active ingredient Cytarabine or Ara-C) remains an indispensable therapeutic agent. As a cell-cycle phase-specific antimetabolite, Cytosar is the cornerstone of induction and maintenance therapy for various forms of leukemia. Its ability to disrupt DNA synthesis makes it a non-negotiable component of modern hematologic protocols. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Cytosar Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical cold-chain logistics. What is Cytosar Injection? Cytosar is a sterile, lyophilized powder or solution for intravenous, intrathecal, or subcutaneous administration, typically available in strengths of 100 mg, 500 mg, 1 g, and 2 g Vials. It is a pyrimidine nucleoside analog that effectively “tricks“ cancer cells during the S-phase of the cell cycle. Primary Therapeutic Indications Acute Myeloid Leukemia (AML): The primary agent for induction therapy (often in the “7+3“ regimen) and consolidation therapy. Acute Lymphocytic Leukemia (ALL): A vital component in pediatric and adult ALL protocols. Chronic Myeloid Leukemia (CML): Used in the blast crisis phase to manage rapid leukemic cell proliferation. Meningeal Leukemia: Administered intrathecally to treat or prevent the spread of leukemia to the central nervous system. Non-Hodgkin’s Lymphoma: Utilized in salvage regimens for aggressive or refractory lymphomas. Technical Product Profile: Cytosar (Cytarabine) Feature Technical Specification Active Ingredient Cytarabine (Ara-C) Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “100 mg, 500 mg, 1 g, 2 g Vials“ Manufacturer Leading GMP Indian Partners Dosage Form Lyophilized Powder / Concentrated Solution for Injection Storage 15°C to 30°C; Protect from light Mechanism of Action: DNA Chain Termination Cytosar exerts its cytotoxic effect by disrupting the synthesis and repair of DNA: Activation: Cytarabine is intracellularly converted into its active form, Cytarabine Triphosphate (Ara-CTP). DNA Polymerase Inhibition: Ara-CTP inhibits DNA polymerase, the enzyme responsible for assembling new DNA strands. Chain Termination: It incorporates itself into the DNA strand, acting as a “faulty brick“ that prevents further elongation and triggers programmed cell death (apoptosis). S-Phase Specificity: It is most lethal to cells actively synthesizing DNA, which is why it is highly effective against rapidly dividing leukemic blasts. Clinical Administration & Safety High-Dose Therapy (HiDAC): In certain consolidation protocols, very high doses are used, necessitating strict monitoring for cerebellar toxicity and ocular side effects (conjunctivitis). Hematologic Monitoring: The primary side effect is significant bone marrow suppression. Regular CBC (Complete Blood Count) monitoring is mandatory. Intrathecal Use: When used for CNS prophylaxis, it must be preservative-free to ensure patient safety. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing prowess to stabilize the global supply of Cytosar. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private hematology centers in London via MHRA-compliant channels. United States: Bulk procurement options for specialized pharmacies, hospital systems, and NCI-designated cancer centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier medical cities and government health authorities. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock for national leukemia treatment programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Gemita Injection (Gemcitabine): Advanced Nucleoside Analog for Solid Tumors – Global Supply by Ernest Oncology In the intensive field of 2026 oncology, Gemita Injection (containing the active ingredient Gemcitabine) remains a cornerstone therapeutic for several challenging malignancies. As a nucleoside metabolic inhibitor, Gemita is globally recognized for its efficacy in disrupting cancer cell replication, particularly in pancreatic, lung, and breast cancers. Its predictable safety profile and versatility in combination therapies make it a staple in both curative and palliative chemotherapy regimens. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Gemita Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Gemita Injection? Gemita is a sterile solution or lyophilized powder for intravenous infusion, typically available in strengths of 200 mg, 1 g, and 1.4 g Vials. It is a pyrimidine antimetabolite that mimics the natural building blocks of DNA to halt tumor growth. Primary Therapeutic Indications Pancreatic Cancer: The gold-standard first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with Cisplatin for the first-line treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Breast Cancer: Used in combination with Paclitaxel for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-based chemotherapy. Ovarian Cancer: Utilized in combination with Carboplatin for patients with advanced ovarian cancer that has relapsed at least six months after completion of platinum-based therapy. Bladder Cancer: Frequently used in the gemcitabine-cisplatin (GC) regimen for advanced or metastatic transitional cell carcinoma. Technical Product Profile: Gemita (Gemcitabine) Feature Technical Specification Brand Name Gemita Active Ingredient Gemcitabine Hydrochloride Pharmacological Class Nucleoside Metabolic Inhibitor (Antimetabolite) Available Strengths “200 mg, 1 g, 1.4 g Vials“ Manufacturer Leading GMP Indian Partners Dosage Form Injection / Lyophilized Powder for IV Infusion Storage 20°C to 25°C; Protect from light Mechanism of Action: DNA Synthesis Inhibition Gemita exerts its cytotoxic effect by “tricking“ the cancer cell during the DNA synthesis (S-phase) of the cell cycle: Metabolic Activation: Gemcitabine is metabolized intracellularly into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Masked Chain Termination: The active triphosphate is incorporated into the DNA strand. After one additional nucleotide is added, the DNA polymerase is unable to proceed, effectively “locking“ the DNA and preventing repair. Dual Action: It also inhibits the enzyme ribonucleotide reductase, reducing the pool of natural deoxynucleotides available for DNA synthesis. Clinical Administration & Safety Infusion Duration: Typically administered as an IV infusion over 30 minutes. Hematologic Monitoring: The primary dose-limiting toxicity is myelosuppression. Regular CBC (Complete Blood Count) monitoring is mandatory. Tolerability: Gemita is generally well-tolerated, often used in elderly populations or patients with lower performance status where more aggressive taxanes might be contraindicated. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Gemita. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Gemcite Injection (Gemcitabine): Advanced Nucleoside Analog for Solid Tumors – Global Supply by Ernest Oncology In the intensive field of 2026 oncology, Gemcite Injection (containing the active ingredient Gemcitabine) remains a cornerstone therapeutic for several challenging malignancies. As a nucleoside metabolic inhibitor, Gemcite is globally recognized for its efficacy in disrupting cancer cell replication, particularly in pancreatic, lung, and breast cancers. Its predictable safety profile and versatility in combination therapies make it a staple in both curative and palliative chemotherapy regimens. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. What is Gemcite Injection? Gemcite is a sterile, lyophilized powder for intravenous infusion, typically available in strengths of 200 mg and 1 g Vials. It is a pyrimidine antimetabolite that mimics the natural building blocks of DNA to halt tumor growth. Primary Therapeutic Indications Pancreatic Cancer: The gold-standard first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with Cisplatin for the first-line treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Breast Cancer: Used in combination with Paclitaxel for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-based chemotherapy. Ovarian Cancer: Utilized in combination with Carboplatin for patients with advanced ovarian cancer that has relapsed at least six months after completion of platinum-based therapy. Bladder Cancer: Frequently used in the gemcitabine-cisplatin (GC) regimen for advanced or metastatic transitional cell carcinoma. Technical Product Profile: Gemcite (Gemcitabine) Feature Technical Specification Brand Name Gemcite Active Ingredient Gemcitabine Hydrochloride Pharmacological Class Nucleoside Metabolic Inhibitor (Antimetabolite) Available Strengths “200 mg, 1 g Vials“ Manufacturer Leading GMP Indian Partners Dosage Form Lyophilized Powder for Reconstitution (IV Infusion) Storage 20°C to 25°C; Reconstituted solution is stable for 24 hours Mechanism of Action: DNA Synthesis Inhibition Gemcite exerts its cytotoxic effect by “tricking“ the cancer cell during the DNA synthesis (S-phase) of the cell cycle: Metabolic Activation: Gemcitabine is metabolized intracellularly into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Masked Chain Termination: The active triphosphate is incorporated into the DNA strand. After one additional nucleotide is added, the DNA polymerase is unable to proceed, effectively “locking“ the DNA and preventing repair. Ribonucleotide Reductase Inhibition: The diphosphate metabolite inhibits the enzyme responsible for creating the building blocks of DNA, depleting the cell's resources and triggering apoptosis. Clinical Administration & Safety Infusion Duration: Typically administered as an IV infusion over 30 minutes. Prolonging the infusion time beyond 60 minutes or increasing the frequency has been shown to increase toxicity. Hematologic Monitoring: The primary dose-limiting toxicity is myelosuppression (anemia, leucopenia, and thrombocytopenia). Regular CBC (Complete Blood Count) monitoring is essential. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Gemcite. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat https://wa.me/919359902383

Gemzar Injection (Gemcitabine): Advanced Nucleoside Analog for Solid Tumors – Global Supply by Ernest Oncology In the intensive field of 2026 oncology, Gemzar Injection (containing the active ingredient Gemcitabine) remains a cornerstone therapeutic for several challenging malignancies. As a nucleoside metabolic inhibitor, Gemzar is globally recognized for its efficacy in disrupting cancer cell replication, particularly in pancreatic, lung, and breast cancers. Its predictable safety profile and versatility in combination therapies make it a staple in both curative and palliative chemotherapy regimens. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. What is Gemzar Injection? (Mechanism & Clinical Indications) Gemzar is a sterile, lyophilized powder for intravenous infusion, typically available in strengths of 200 mg and 1 g Vials. It is a pyrimidine antimetabolite that mimics the natural building blocks of DNA to halt tumor growth. Primary Therapeutic Indications Pancreatic Cancer: The gold-standard first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with Cisplatin for the first-line treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Breast Cancer: Used in combination with Paclitaxel for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-based chemotherapy. Ovarian Cancer: Utilized in combination with Carboplatin for patients with advanced ovarian cancer that has relapsed at least six months after completion of platinum-based therapy. Bladder Cancer: Frequently used in the gemcitabine-cisplatin (GC) regimen for advanced or metastatic transitional cell carcinoma. Technical Product Profile: Gemzar (Gemcitabine) Feature Technical Specification Brand Name Gemzar Active Ingredient Gemcitabine Hydrochloride Pharmacological Class Nucleoside Metabolic Inhibitor (Antimetabolite) Available Strengths “200 mg, 1 g, 2 g Vials“ Manufacturer Eli Lilly / Leading GMP Indian Partners Dosage Form Lyophilized Powder for Reconstitution (IV Infusion) Storage 20°C to 25°C; Reconstituted solution is stable for 24 hours Mechanism of Action: DNA Synthesis Inhibition Gemzar exerts its cytotoxic effect by “tricking“ the cancer cell during the DNA synthesis (S-phase) of the cell cycle: Metabolic Activation: Gemcitabine is metabolized intracellularly into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Masked Chain Termination: The active triphosphate is incorporated into the DNA strand. After one additional nucleotide is added, the DNA polymerase is unable to proceed, effectively “locking“ the DNA and preventing repair. Ribonucleotide Reductase Inhibition: The diphosphate metabolite inhibits the enzyme responsible for creating the building blocks of DNA, depleting the cell's resources and triggering apoptosis. Clinical Administration & Safety Infusion Duration: Typically administered as an IV infusion over 30 minutes. Prolonging the infusion time beyond 60 minutes or increasing the frequency has been shown to increase toxicity. Hematologic Monitoring: The primary dose-limiting toxicity is myelosuppression (anemia, leucopenia, and thrombocytopenia). Regular CBC (Complete Blood Count) monitoring is essential. Ease of Use: Gemzar is generally well-tolerated, with a lower incidence of severe alopecia (hair loss) compared to many other cytotoxic agents. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Gemzar. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 0238

Fluoroblast Injection (Fluorouracil): Advanced Antimetabolite Therapy for Solid Tumors – Global Supply by Ernest Oncology In the core of modern oncology protocols, Fluoroblast Injection (containing the active ingredient Fluorouracil) remains one of the most critical and widely prescribed chemotherapy agents. As a pyrimidine antagonist, Fluoroblast has been a mainstay in cancer treatment for decades, serving as the backbone for legendary regimens like FOLFOX, FOLFIRI, and CMF. Its ability to inhibit DNA synthesis makes it indispensable for treating a broad spectrum of solid tumors across global healthcare systems. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified Fluoroblast Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, supported by validated 2026 global logistics. What is Fluoroblast Injection? (Mechanism & Clinical Role) Fluoroblast is a sterile, aqueous solution for intravenous administration, typically available in concentrations of 50 mg/mL (e.g., 250 mg, 500 mg, 1000 mg, and 5000 mg vials). As an antimetabolite, it mimics the building blocks of DNA to disrupt cancer cell growth. Primary Therapeutic Indications Colorectal Cancer: The primary component in adjuvant and metastatic treatment protocols. Breast Cancer: Frequently used in combination with cyclophosphamide and methotrexate (CMF regimen). Gastric & Pancreatic Cancer: A vital part of multi-drug regimens to improve survival outcomes in GI malignancies. Esophageal & Head and Neck Cancers: Often used as a radiosensitizer to enhance the efficacy of radiation therapy. Technical Product Profile: Fluoroblast (Fluorouracil) Feature Technical Specification Brand Name Fluoroblast Active Ingredient Fluorouracil (5-FU) Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “250mg, 500mg, 1000mg, 2500mg, 5000mg Vials“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Solution for Intravenous Injection or Infusion Storage 15°C to 30°C; Protect from light; Do Not Refrigerate (to prevent precipitation) Mechanism of Action: Thymidylate Synthase Inhibition Fluoroblast exerts its cytotoxic effects by “tricking“ the cancer cell during the S-phase of the cell cycle: Metabolic Conversion: Once administered, the active ingredient is converted intracellularly into active metabolites (F-UMP, F-dUMP). Enzyme Blockade: It binds to the enzyme Thymidylate Synthase, which is essential for the production of thymidine (a DNA “brick“). DNA/RNA Disruption: By depriving the cell of thymidine, it causes “thymineless death.“ It also incorporates itself into RNA, further disrupting protein synthesis and triggering apoptosis. Clinical Administration & Safety Leucovorin Potentiation: Fluoroblast is often administered with Leucovorin (Folinic Acid), which binds with the active metabolite to the enzyme, making the treatment significantly more potent. Infusion Methods: It can be given as a rapid “bolus“ injection or as a continuous long-term infusion via a portable pump to maximize exposure to cancer cells. Safety Monitoring: Patients must be monitored for stomatitis (mouth sores), diarrhea, and “hand-foot syndrome.“ DPD Deficiency: Use with extreme caution in patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, as they cannot metabolize the drug normally. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing prowess to stabilize the global supply of Fluoroblast. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private oncology centers via MHRA-compliant channels. United States: Bulk supply for specialized pharmacies and hospital groups, supporting essential oncology care. Abu Dhabi & UAE: Fast-tracked export to the Middle East's growing oncology hubs, ensuring rapid availability for government tenders. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock levels for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

5-FU Injection (Fluorouracil): The Core Antimetabolite for Advanced Oncology Regimens – Global Supply by Ernest Oncology In the landscape of 2026 oncology, 5-FU Injection (5-Fluorouracil) remains an absolute cornerstone of chemotherapy. As a potent pyrimidine antagonist, it is the backbone of the world’s most successful cancer treatment protocols, including FOLFOX, FOLFIRI, and FOLFIRINOX. Its ability to selectively inhibit the synthesis of DNA and RNA makes it indispensable for treating a vast array of solid tumors across global healthcare systems. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified 5-FU Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, supported by validated cold-chain logistics. What is 5-FU Injection? (Mechanism & Clinical Role) 5-FU is a sterile, aqueous solution for intravenous administration, typically available in strengths of 250 mg, 500 mg, 1000 mg, 2500 mg, and 5000 mg Vials (50 mg/mL concentration). It is classified as an antimetabolite, specifically a fluorinated pyrimidine. Primary Therapeutic Indications Colorectal Carcinoma: The primary component for both adjuvant and metastatic treatment of colon and rectal cancers. Breast Cancer: Frequently utilized in combination regimens such as CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil). Gastric & Pancreatic Cancer: A vital part of multi-drug protocols used to improve survival in gastrointestinal malignancies. Head and Neck Cancers: Often used as a radiosensitizer to increase the efficacy of concurrent radiation therapy. Dermatological Application: Occasionally used topically or via injection for certain pre-cancerous skin lesions and superficial basal cell carcinomas. Technical Product Profile: 5-FU (Fluorouracil) Feature Technical Specification Active Ingredient 5-Fluorouracil Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “250mg, 500mg, 1000mg, 2500mg, 5000mg Vials“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Solution for IV Injection or Continuous Infusion Storage 15°C to 30°C; Protect from light; Do Not Refrigerate (to avoid crystal formation) Mechanism of Action: Thymineless Death 5-FU exerts its cytotoxic effects by mimicking the natural building blocks of the cell: Thymidylate Synthase Inhibition: 5-FU is converted into active metabolites (F-dUMP) that bind to the enzyme thymidylate synthase. This prevents the production of thymidine, which is essential for DNA replication. RNA Incorporation: Active metabolites (F-UTP) are mistakenly incorporated into RNA, disrupting normal protein synthesis and cellular function. S-Phase Specificity: It is most effective during the S-phase of the cell cycle, leading to “thymineless death“ in rapidly dividing malignant cells. Clinical Administration & Safety Leucovorin Potentiation: 5-FU is often administered with Leucovorin (Folinic Acid), which stabilizes the binding of 5-FU to the target enzyme, significantly increasing its therapeutic potency. Administration Methods: It can be delivered via rapid bolus injection or as a continuous 24–48 hour infusion using specialized infusion pumps to maintain constant therapeutic levels. Safety Monitoring: Common side effects include stomatitis, diarrhea, and Hand-Foot Syndrome. Clinicians must screen for DPD (Dihydropyrimidine Dehydrogenase) deficiency, as patients with this genetic trait cannot metabolize the drug safely. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology bridges the gap between high-quality Indian pharmaceutical manufacturing and global patient needs. We ensure that every batch of 5-FU reaches its destination with full documentation and regulatory compliance. United Kingdom & London: Reliable supply to NHS Trusts and private oncology clinics via MHRA-compliant supply chains. United States: Bulk procurement options for specialty pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383